Table 1.

Cohort clinical characteristics

Patient ID	Age	Sex	CD4 cell count (cells/μL)	VL (copies/mL)	Time on suppressive ART (years)	Current ART treatment regimena	Assay	No. of LN Mononuclear cells collected (million)	Purity LN resident DCs (%)	Purity LN migratory DCs (%)	Purity LN CD4/PD-1+ or PD-1−CD4 T cells
#118	28	M	538	1.40E + 4	viremic	N/A	CA, TILDA, viral production	360	99	99	100
#128	30	M	158	2.50E + 4	viremic	N/A	viral production	150	99.8	98.1	99
#148	37	M	717	2.00E + 4	viremic	N/A	MC	120	N/A	N/A	N/A
#149	38	M	280	1.80E + 4	viremic	N/A	MC, TILDA, viral production	150	100	98.1	99
#157	22	M	507	1.90E + 3	viremic	N/A	MC, INT DNA, CA	100	99	100	98
#158	28	M	279	3.10E + 5	viremic	N/A	MC, INT DNA, CA	90	99.1	100	100
#1001	27	M	655	3.22E + 4	viremic	N/A	INT DNA	N/D	98.6	100	100
#1003	30	M	913	6.96E + 4	viremic	N/A	MC	N/D	N/A	N/A	N/A
#1008	23	M	566	4.94E + 5	viremic	N/A	MC, CA, TILDA	N/D	98.2	98.4	99.4
#1009	45	M	894	1.79E + 4	viremic	N/A	MC	N/D	N/A	N/A	N/A
#1010	35	M	803	1.44E + 4	viremic	N/A	CA, TILDA, viral production	N/D	100	98.5	100
#1013	50	F	428	2.15E + 5	viremic	N/A	INT DNA, viral production	N/D	99.8	100	99.3
#1014	29	M	381	4.16E + 5	viremic	N/A	MC, viral production	N/D	99.3	99.1	100
#1017	37	F	498	1.74E + 4	viremic	N/A	INT DNA	N/D	99	99.5	98.1
#1019	31	M	855	1.79E + 4	viremic	N/A	HIV sequencing	N/D	98	100	98
#1024	31	M	546	4.63E + 4	viremic	N/A	HIV sequencing	N/D	99	100	98.1
#1025	29	M	637	1.21E + 5	viremic	N/A	MC, HIV sequencing	N/D	99.1	98	98.3
#1027	31	F	521	6.08E + 4	viremic	N/A	MC	N/D	N/A	N/A	N/A
#161	56	M	677	<50	5	TDF, FTC, DRV/r	MC, INT DNA, CA, TILDA, VOA	80	99.4	99.1	98.9
#136	44	M	1,326	<50	10	3TC, ABC, RAL	scRNA-seq, MC, VOA, DC-T cell stimulation	150	98.5	98	98.1
#109	44	M	625	<50	0.5	FTC, TDF	MC, INT DNA, TILDA, VOA, RAM	60	100	100	100
#082	52	M	955	<50	2.2	3TC/AZT, IDV	scRNA-seq, INT DNA, CA RNA, TILDA	80	100	98.2	98
#142	37	F	272	<50	14	FTC, TDF, DRV/r	MC, VOA, DC-T cell stimulation	90	100	98.3	98.5
#122	35	M	517	<50	19	DTG, ABC, 3TC	MC, INT DNA, VOA	85	100	100	98
#078	39	M	728	<50	4.6	FTC, TDF, EFV	MC	60	N/A	N/A	N/A
#058–2	48	F	666	<50	12	3TC/AZT, EFV	MC	40	N/A	N/A	N/A
#075	44	M	417	<50	3.2	FTC, TDF, EFV	MC	90	N/A	N/A	N/A
#103	41	M	318	<50	1.1	FTC, TDF, EFV	MC, VOA	100	100	100	100
#155	43	F	852	<50	1	NVP, 3TC, FTC	MC	10	N/A	N/A	N/A
#139	35	M	571	<50	7.5	FTC, TDF, EFV	MC	30	N/A	N/A	N/A
#163	34	F	699	<50	17	FTC, TDF, RPV	MC	10	N/A	N/A	N/A
#159	45	M	336	<50	6	EVG, FTC, TDF	VOA	40	100	100	100
#104	41	F	448	<50	4	FTC, TDF, RPV	VOA, RAM	50	99.2	98	98
#133	41	M	709	<50	8	FTC, TDF, EVG	VOA, RAM	60	100	100	100
#011–2	54	M	954	<50	12	ATV/r, FTC, TDF	scRNA-seq, CA	120	100	100	98
#R003	33	M	902	<50	2.9	FTC, TDF, RPV	QVOA	20	QVOA pool:	QVOA pool:	QVOA pool:
#045	41	M	442	<50	7.6	FTC, TDF, ETR	QVOA	78	100	98.1	99
#105	46	F	712	<50	7.9	DRV/r, RAL, MVC	QVOA	10
#099	46	M	437	<50	3.5	FTC, TDF, RTV, ATV	QVOA	27
#094	46	M	440	<50	6.6	FTC, TDF, EVG	QVOA	68
#093	41	F	438	<50	4.7	ABC, DTG, 3TC	QVOA	17.5
#169	30	M	336	<50	4	RPV/DTG	DC-T cell stimulation	40	100	99.1	99

Related to Figures 1, 2, 3, 4, 5, and 6.

^aAbbreviations: VL, viral load at sampling date; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; RTV, ritonavir; ATV, atazanavir; ATV/r, atazanavir boosted with ritonavir; 3TC, lamivudine; ABC, abacavir; EFV, efavirenz; EVG, elvitegravir; RAL, raltegravir; DTG, dolutegrvir; AZT, zidovudine; DRV/r, darunavir boosted with ritonavir; IDV, idinavir; NVP, nevirapine; RPV, rilpivirine; ETR, etravirine; MVC, maraviroc; scRNA-seq, single-cell RNA sequencing; MC, mass cytometry; INT DNA, integrated DNA; CA, cell-associated HIV RNA; TILDA, tat-rev limiting dilution assay; VOA, viral outgrowth assay; QVOA, quantitative viral outgrowth assay; RAM, resistance associated mutation; N/A, not applicable; N/D, not determined. Time on suppressive ART refers to the time that the individual maintained continuous suppression of viremia to below the limit of detection up until the sampling date.